title: Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs.
abstract: BACKGROUND
  Strategies to stage and treat cancer rely on a presumption of either localized or widespread metastatic disease. An intermediate state of metastasis termed oligometastasis(es) characterized by limited progression has been proposed. Oligometastases are amenable to treatment by surgical resection or radiotherapy.
  
  
  METHODS
  We analyzed microRNA expression patterns from lung metastasis samples of patients with ≤ 5 initial metastases resected with curative intent.
  
  
  RESULTS
  Patients were stratified into subgroups based on their rate of metastatic progression. We prioritized microRNAs between patients with the highest and lowest rates of recurrence. We designated these as high rate of progression (HRP) and low rate of progression (LRP); the latter group included patients with no recurrences. The prioritized microRNAs distinguished HRP from LRP and were associated with rate of metastatic progression and survival in an independent validation dataset.
  
  
  CONCLUSIONS
  Oligo- and poly- metastasis are distinct entities at the clinical and molecular level.
authors.affiliation: Comprehensive Cancer Center, The University of Chicago, Chicago, Illinois, United States of America. yLussier@uic.edu
authors.forename: Yves A
authors.initials: YA
authors.lastname: Lussier
authors.forename: Nikolai N
authors.initials: NN
authors.lastname: Khodarev
authors.forename: Kelly
authors.initials: K
authors.lastname: Regan
authors.forename: Kimberly
authors.initials: K
authors.lastname: Corbin
authors.forename: Haiquan
authors.initials: H
authors.lastname: Li
authors.forename: Sabha
authors.initials: S
authors.lastname: Ganai
authors.forename: Sajid A
authors.initials: SA
authors.lastname: Khan
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Gnerlich
authors.forename: Jennifer
authors.initials: J
authors.lastname: Gnerlich
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Darga
authors.forename: Hanli
authors.initials: H
authors.lastname: Fan
authors.forename: Oleksiy
authors.initials: O
authors.lastname: Karpenko
authors.forename: Philip B
authors.initials: PB
authors.lastname: Paty
authors.forename: Mitchell C
authors.initials: MC
authors.lastname: Posner
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Chmura
authors.forename: Samuel
authors.initials: S
authors.lastname: Hellman
authors.forename: Mark K
authors.initials: MK
authors.lastname: Ferguson
authors.forename: Ralph R
authors.initials: RR
authors.lastname: Weichselbaum
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000401:mortality / Q000556:secondary*; D018450:Disease Progression; D006801:Humans; D008168:Lung / Q000378:metabolism / Q000473:pathology*; D008175:Lung Neoplasms / Q000235:genetics* / Q000401:mortality / Q000556:secondary*; D035683:MicroRNAs / Q000235:genetics* / Q000378:metabolism; D015996:Survival Rate
chemical_list: D035683:MicroRNAs